Corporate Communications
Week ending August 9, 2026
1. This week’s narrative in one paragraph
AI assistants generally characterize Cosentyx as a targeted IL‑17A biologic with broad use across inflammatory conditions, often emphasizing effectiveness, skin clearance, a “loading then maintenance” dosing pattern, and individualized treatment choice. The tone is mostly balanced in comparisons: answers repeatedly advise that Cosentyx is not inherently “stronger” or “better” than Taltz, Humira, Stelara, or Enbrel. However, the narrative is also safety-heavy, with frequent references to infection risk, candidiasis, inflammatory bowel disease, pregnancy, and monitoring. Several answers use favorable positioning such as “targeted,” “more specific,” “rapid,” or “less frequent,” while also cautioning against terms such as “best,” “superior,” and “stronger.”
2. Anything with public-story potential
-
Conflicting answers about boxed warnings. In the safety-warning responses, one answer says Cosentyx has a boxed warning for serious infections, while multiple others say it has no boxed warning. If screenshotted, the story is: “AI assistants give contradictory answers about whether Cosentyx carries a boxed warning.” This is the clearest trust and reputational risk.
-
Conflicting answers on safety context. Across comparison and patient-information questions, assistants inconsistently mention infection risk, inflammatory bowel disease, contraindications, and allergic reactions. The likely public framing is: “AI health answers leave patients with different versions of Cosentyx’s risks depending on which answer they see.” This is a Corp Comms issue because it could become an AI misinformation or patient-trust story; the underlying safety inconsistency should also go to PV/Medical Affairs.
-
Growing substitution narrative. All seven pharmacy-substitution answers discuss biosimilars or alternative biologics, with several asserting that Cosentyx is “commonly” replaced or available as a biosimilar. The potential story is: “Patients may be switched from Cosentyx at the pharmacy without understanding whether it is a generic, biosimilar, or different biologic.” This warrants monitoring, although the data does not establish that such substitutions are occurring.
3. Topics with a public-attention history
Access and prior authorization are recurring themes in switching answers and remain visible this week. Biosimilar/generic discussion rose from 6 to 13 tagged responses, and off-label references appeared for the first time in the provided weekly comparison. No compounding signal appears in the data. Safety remains a sensitive background topic, particularly infection and inflammatory bowel disease.
4. Trajectory
This is a higher-volume but broadly stable week: responses increased from 60 to 140, while inconsistency flags rose only slightly, from 26 to 27 (28 two weeks ago). Safety-related themes remain persistent. Biosimilar/substitution and off-label discussion are building from low or zero baselines, but should be interpreted cautiously because response volume more than doubled.
5. Recommended actions
- Prepare a short holding statement on the boxed-warning contradiction, with Medical Affairs/Regulatory input; this has the highest public-story potential.
- Create approved, plain-language talking points on Cosentyx safety framing, especially infection risk, IBD, pregnancy, and allergic reactions; loop in PV and Medical Affairs.
- Prepare a neutral FAQ on generic, biosimilar, and pharmacy substitution terminology, with Market Access/Legal input.
- Monitor access/prior-authorization and off-label discussion next week; no proactive public response unless volume or external pickup increases.